What Researchers Did
Researchers reviewed evidence from 1990 to 2008 to determine the prevalence of osteoradionecrosis (ORN) in head and neck cancer patients treated with various therapies and to evaluate management strategies.
What They Found
After reviewing 43 articles, the weighted prevalence of osteoradionecrosis (ORN) was found to be 7.4% for conventional radiotherapy, 5.1% for intensity-modulated radiotherapy, 6.8% for chemoradiotherapy, and 5.3% for brachytherapy. While hyperbaric oxygen may play a role in management, no clear guideline recommendations for ORN prevention or treatment could be established from the reviewed literature.
What This Means for Canadian Patients
Canadian head and neck cancer patients undergoing radiotherapy or chemoradiotherapy should be aware of the varying risks of osteoradionecrosis (ORN) associated with different treatment types. Given the absence of clear guidelines for ORN prevention and treatment, patients should discuss all potential risks and management options thoroughly with their oncology team.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
A key limitation was the inability to establish clear guideline recommendations for ORN prevention or treatment due to the nature of the available literature.